Cargando…

The Antibody Society’s antibody validation webinar series

In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commerc...

Descripción completa

Detalles Bibliográficos
Autores principales: Voskuil, Jan L.A., Bandrowski, Anita, Begley, C. Glenn, Bradbury, Andrew R.M., Chalmers, Andrew D., Gomes, Aldrin V., Hardcastle, Travis, Lund-Johansen, Fridtjof, Plückthun, Andreas, Roncador, Giovanna, Solache, Alejandra, Taussig, Michael J., Trimmer, James S., Williams, Cecilia, Goodman, Simon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531563/
https://www.ncbi.nlm.nih.gov/pubmed/32748696
http://dx.doi.org/10.1080/19420862.2020.1794421
_version_ 1783589781534408704
author Voskuil, Jan L.A.
Bandrowski, Anita
Begley, C. Glenn
Bradbury, Andrew R.M.
Chalmers, Andrew D.
Gomes, Aldrin V.
Hardcastle, Travis
Lund-Johansen, Fridtjof
Plückthun, Andreas
Roncador, Giovanna
Solache, Alejandra
Taussig, Michael J.
Trimmer, James S.
Williams, Cecilia
Goodman, Simon L.
author_facet Voskuil, Jan L.A.
Bandrowski, Anita
Begley, C. Glenn
Bradbury, Andrew R.M.
Chalmers, Andrew D.
Gomes, Aldrin V.
Hardcastle, Travis
Lund-Johansen, Fridtjof
Plückthun, Andreas
Roncador, Giovanna
Solache, Alejandra
Taussig, Michael J.
Trimmer, James S.
Williams, Cecilia
Goodman, Simon L.
author_sort Voskuil, Jan L.A.
collection PubMed
description In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds. This report highlights the problems, and offers solutions to help the scientific community appropriately identify the right antibodies and to validate them for their research and development projects. Despite the various solutions proposed here, they must be applied on a case-by-case basis. Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity. Verification needs to focus on the precise application and tissue/cell type for which the antibody will be used, and all verification data must be reported openly. The various approaches discussed here all have caveats, so a combination of solutions must be considered.
format Online
Article
Text
id pubmed-7531563
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-75315632020-10-13 The Antibody Society’s antibody validation webinar series Voskuil, Jan L.A. Bandrowski, Anita Begley, C. Glenn Bradbury, Andrew R.M. Chalmers, Andrew D. Gomes, Aldrin V. Hardcastle, Travis Lund-Johansen, Fridtjof Plückthun, Andreas Roncador, Giovanna Solache, Alejandra Taussig, Michael J. Trimmer, James S. Williams, Cecilia Goodman, Simon L. MAbs Perspective In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds. This report highlights the problems, and offers solutions to help the scientific community appropriately identify the right antibodies and to validate them for their research and development projects. Despite the various solutions proposed here, they must be applied on a case-by-case basis. Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity. Verification needs to focus on the precise application and tissue/cell type for which the antibody will be used, and all verification data must be reported openly. The various approaches discussed here all have caveats, so a combination of solutions must be considered. Taylor & Francis 2020-08-04 /pmc/articles/PMC7531563/ /pubmed/32748696 http://dx.doi.org/10.1080/19420862.2020.1794421 Text en © 2020 The Authors. Published with license by Taylor & Francis, LLC https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspective
Voskuil, Jan L.A.
Bandrowski, Anita
Begley, C. Glenn
Bradbury, Andrew R.M.
Chalmers, Andrew D.
Gomes, Aldrin V.
Hardcastle, Travis
Lund-Johansen, Fridtjof
Plückthun, Andreas
Roncador, Giovanna
Solache, Alejandra
Taussig, Michael J.
Trimmer, James S.
Williams, Cecilia
Goodman, Simon L.
The Antibody Society’s antibody validation webinar series
title The Antibody Society’s antibody validation webinar series
title_full The Antibody Society’s antibody validation webinar series
title_fullStr The Antibody Society’s antibody validation webinar series
title_full_unstemmed The Antibody Society’s antibody validation webinar series
title_short The Antibody Society’s antibody validation webinar series
title_sort antibody society’s antibody validation webinar series
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531563/
https://www.ncbi.nlm.nih.gov/pubmed/32748696
http://dx.doi.org/10.1080/19420862.2020.1794421
work_keys_str_mv AT voskuiljanla theantibodysocietysantibodyvalidationwebinarseries
AT bandrowskianita theantibodysocietysantibodyvalidationwebinarseries
AT begleycglenn theantibodysocietysantibodyvalidationwebinarseries
AT bradburyandrewrm theantibodysocietysantibodyvalidationwebinarseries
AT chalmersandrewd theantibodysocietysantibodyvalidationwebinarseries
AT gomesaldrinv theantibodysocietysantibodyvalidationwebinarseries
AT hardcastletravis theantibodysocietysantibodyvalidationwebinarseries
AT lundjohansenfridtjof theantibodysocietysantibodyvalidationwebinarseries
AT pluckthunandreas theantibodysocietysantibodyvalidationwebinarseries
AT roncadorgiovanna theantibodysocietysantibodyvalidationwebinarseries
AT solachealejandra theantibodysocietysantibodyvalidationwebinarseries
AT taussigmichaelj theantibodysocietysantibodyvalidationwebinarseries
AT trimmerjamess theantibodysocietysantibodyvalidationwebinarseries
AT williamscecilia theantibodysocietysantibodyvalidationwebinarseries
AT goodmansimonl theantibodysocietysantibodyvalidationwebinarseries
AT voskuiljanla antibodysocietysantibodyvalidationwebinarseries
AT bandrowskianita antibodysocietysantibodyvalidationwebinarseries
AT begleycglenn antibodysocietysantibodyvalidationwebinarseries
AT bradburyandrewrm antibodysocietysantibodyvalidationwebinarseries
AT chalmersandrewd antibodysocietysantibodyvalidationwebinarseries
AT gomesaldrinv antibodysocietysantibodyvalidationwebinarseries
AT hardcastletravis antibodysocietysantibodyvalidationwebinarseries
AT lundjohansenfridtjof antibodysocietysantibodyvalidationwebinarseries
AT pluckthunandreas antibodysocietysantibodyvalidationwebinarseries
AT roncadorgiovanna antibodysocietysantibodyvalidationwebinarseries
AT solachealejandra antibodysocietysantibodyvalidationwebinarseries
AT taussigmichaelj antibodysocietysantibodyvalidationwebinarseries
AT trimmerjamess antibodysocietysantibodyvalidationwebinarseries
AT williamscecilia antibodysocietysantibodyvalidationwebinarseries
AT goodmansimonl antibodysocietysantibodyvalidationwebinarseries